AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15617914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 80
Study 15617914 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 80
Study 11379679 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 30 mg ketorolac administered before tourniquet inflation
Number of subjects: 48
Study 11379679 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 30 mg ketorolac administered after tourniquet inflation
Number of subjects: 48
Study 9931687 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine substitution
Number of subjects: 34
Study 9931687 — intervention group
Group type: COMPARATOR
Intervention: No glutamine substitution (Control)
Number of subjects: 34
Study 7833219 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl-arginine (L-NMMA) 4 mumol min-1 for 5 min
Number of subjects: 6
Study 7833219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin 10 and 100 pmol min-1 for 3 min each dose
Number of subjects: 6
Study 7833219 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 2 and 5 nmol min-1 for 3 min each dose
Number of subjects: 6
Study 7833219 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA
Number of subjects: 6
Study 3122983 — intervention group
Group type: COMPARATOR
Intervention: Double contrast barium enema examination
Number of subjects: 168
Study 3122983 — intervention group
Group type: EXPERIMENTAL
Intervention: Total colonoscopy
Number of subjects: 168
Study 31714270 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ECMO
Number of subjects: 0
Study 31714270 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 0
Study 31714270 — intervention group
Group type: COMPARATOR
Intervention: CPB
Number of subjects: 0
Study 30896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically lowered 25(OH)D levels
Number of subjects: 4254
Study 30896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D Genetic Risk Score (VD_GRS)
Number of subjects: 4254
Study 30896763 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined per‐SD increase for 25(OH)D
Number of subjects: 4254
Study 28362531 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 17
Study 26218494 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatients
Number of subjects: 1064
Study 26218494 — intervention group
Group type: COMPARATOR
Intervention: Inpatients
Number of subjects: 1064
Study 23612559 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in cell phone conversations while driving
Number of subjects: 0
Study 23612559 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone conversations as a secondary task
Number of subjects: 0
Study 23612559 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to road conditions before engaging in calls
Number of subjects: 0
Study 21732894 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 106
Study 21732894 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 106
Study 19628666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin B(2) receptor blocker HOE‐140
Number of subjects: 9
Study 19628666 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 9
Study 16638295 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD)
Number of subjects: 0
Study 16638295 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-SSD)
Number of subjects: 0
Study 15220769 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral Entropy (SE)
Number of subjects: 10
Study 15220769 — intervention group
Group type: EXPERIMENTAL
Intervention: Response Entropy (RE)
Number of subjects: 10
Study 15220769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 10
Study 15220769 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐Line ARX Index (AAI)
Number of subjects: 10
Study 11292401 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure with Goldmann applanation tonometry
Number of subjects: 15
Study 11292401 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted eyelid closure with Tono-pen XL
Number of subjects: 15
Study 11292401 — intervention group
Group type: COMPARATOR
Intervention: Tono-pen XL
Number of subjects: 15
Study 9432036 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow (ABM) transplantation
Number of subjects: 67
Study 9432036 — intervention group
Group type: COMPARATOR
Intervention: Blood stem cell (BSC) transplantation
Number of subjects: 67
Study 9432036 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro culture
Number of subjects: 67
Study 9432036 — intervention group
Group type: EXPERIMENTAL
Intervention: T-NHL
Number of subjects: 67
Study 9432036 — intervention group
Group type: EXPERIMENTAL
Intervention: t(14;18)+ B-NHL
Number of subjects: 67
Study 9432036 — intervention group
Group type: EXPERIMENTAL
Intervention: B-NHLs without t(14,18)
Number of subjects: 67
Study 8845473 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 100 mg/m2/day for 5 days
Number of subjects: 27
Study 8845473 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 75 mg/m2/day for 5 days
Number of subjects: 27
Study 8845473 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate (EP) at 50 or 75 mg/m2/day for 5 days
Number of subjects: 27
Study 2225518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimony electrode (after finger calibration)
Number of subjects: 10
Study 2225518 — intervention group
Group type: COMPARATOR
Intervention: Glass electrode
Number of subjects: 10
Study 2225518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimony electrode (beaker calibration)
Number of subjects: 10
Study 2225518 — intervention group
Group type: COMPARATOR
Intervention: Glass electrode (beaker calibration)
Number of subjects: 10
Study 667676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram/kg)
Number of subjects: 53
Study 667676 — intervention group
Group type: COMPARATOR
Intervention: Alfathesin alone
Number of subjects: 53
Study 30522048 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release naltrexone (XR‐NTX)
Number of subjects: 300
Study 30522048 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 300
Study 28110290 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone internet-based vestibular rehabilitation (VR)
Number of subjects: 0
Study 28110290 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based VR with physiotherapeutic support ('blended care')
Number of subjects: 0
Study 28110290 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25850865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control with insulin (insulin titrated to maintain blood glucose between 80 and 110 mg/dL)
Number of subjects: 561
Study 25850865 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 561
Study 25029368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 2 hour post challenge plasma glucose, family history of diabetes
Number of subjects: 8400
Study 25029368 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist circumference
Number of subjects: 8400
Study 25029368 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist/height ratio
Number of subjects: 8400
Study 25029368 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 8400
Study 25029368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low education level
Number of subjects: 8400
Study 22192068 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol 2 g b.i.d. (n = 40)
Number of subjects: 80
Study 22192068 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 40)
Number of subjects: 80
Study 22192068 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol 2 g b.i.d.
Number of subjects: 80
Study 22192068 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 20668885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline in 5% dextrose at the standard maintenance rate (Group A)
Number of subjects: 167
Study 20668885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18% saline in 5% dextrose at the standard maintenance rate (Group B)
Number of subjects: 167
Study 20668885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.18% saline in 5% dextrose at two-thirds of the standard maintenance rate (Group C)
Number of subjects: 167
Study 17461738 — intervention group
Group type: COMPARATOR
Intervention: Cholinesterase inhibitors
Number of subjects: 0
Study 17461738 — intervention group
Group type: COMPARATOR
Intervention: Memantine
Number of subjects: 0
Study 15660059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous, intraoperative unfractionated heparin
Number of subjects: 134
Study 15660059 — intervention group
Group type: COMPARATOR
Intervention: Intravenous, intraoperative saline (Control)
Number of subjects: 134
Study 11877611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (dalteparin: 2,500 IU for ≤70 kg and 5,000 IU for >70 kg, started perioperatively and given once daily for 4 weeks)
Number of subjects: 130
Study 11877611 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 130
Study 10571698 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid treatment
Number of subjects: 13
Study 10571698 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis of thyrotoxicosis
Number of subjects: 13
Study 8701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 mcg (b.i.d.)
Number of subjects: 59
Study 8701511 — intervention group
Group type: COMPARATOR
Intervention: Oral salbutamol controlled release 8 mg (b.i.d.)
Number of subjects: 59
Study 2071282 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration
Number of subjects: 0
Study 2071282 — intervention group
Group type: COMPARATOR
Intervention: Control (no bupivacaine infiltration)
Number of subjects: 0
Study 6866678 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-training once every 2 weeks
Number of subjects: 48
Study 6866678 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-training once every 4 weeks
Number of subjects: 48
Study 6866678 — intervention group
Group type: COMPARATOR
Intervention: No re-training
Number of subjects: 48
Study 31655449 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous distractors moving in the same direction
Number of subjects: 0
Study 31655449 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous distractors moving in randomized directions
Number of subjects: 0
Study 31655449 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving target without direction change
Number of subjects: 0
Study 28326569 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (20-40 mg daily)
Number of subjects: 554
Study 28326569 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery (LARS)
Number of subjects: 554
Study 28326569 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 554
Study 25692384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rapamycin gel, 0.2%, applied twice a day for 12 weeks
Number of subjects: 6
Study 25692384 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical rapamycin treatment
Number of subjects: 6
Study 23434908 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement (12 mg of lutein and 280 mg of DHA daily)
Number of subjects: 44
Study 23434908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19681943 — intervention group
Group type: EXPERIMENTAL
Intervention: TiO(2) thin film modified implants
Number of subjects: 15
Study 19681943 — intervention group
Group type: COMPARATOR
Intervention: Unmodified microimplants
Number of subjects: 15
Study 19883343 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-nurses-led intervention for establishing a clinical trial
Number of subjects: 59
Study 19883343 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and training for practice nurses (PNs)
Number of subjects: 59
Study 16696748 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including occupational and physical therapy sessions, home modifications, problem-solving strategies, energy conservation, safe performance techniques, fall recovery techniques, balance and muscle strength training.
Number of subjects: 319
Study 14980903 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (12 microg x kg(‐1) x min(‐1) for 10 min followed by 4 microg x kg(‐1) x min(‐1))
Number of subjects: 18
Study 14980903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14980903 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 18
Study 11570838 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Matters program
Number of subjects: 1014
Study 1564023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release methylphenidate (MPH)
Number of subjects: 19
Study 1564023 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard methylphenidate (MPH)
Number of subjects: 19
Study 1564023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of standard and sustained-release MPH
Number of subjects: 19
Study 1564023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3900181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet
Number of subjects: 7
Study 3900181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 7
Study 31978843 — intervention group
Group type: EXPERIMENTAL
Intervention: PechaKucha presentation method
Number of subjects: 134
Study 31978843 — intervention group
Group type: COMPARATOR
Intervention: Traditional PowerPoint presentation
Number of subjects: 134
Study 29544062 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO drink (75 g CHO)
Number of subjects: 13
Study 29544062 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO drink (60.5 g CHO and 14.5 g PRO)
Number of subjects: 13
Study 29544062 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (PLA)
Number of subjects: 13
Study 29544062 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (CHO, CHO+PRO, PLA)
Number of subjects: 13
Study 26941579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol plasma coagulation (AePC)
Number of subjects: 34
Study 26941579 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection (SR)
Number of subjects: 34
Study 23740619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (Diabetes Prevention Program)
Number of subjects: 72
Study 23740619 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-and-steady cluster
Number of subjects: 72
Study 23740619 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest cluster
Number of subjects: 72
Study 22571514 — intervention group
Group type: EXPERIMENTAL
Intervention: Wellness intervention group
Number of subjects: 60
Study 22571514 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control with release time
Number of subjects: 60
Study 22571514 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control with routine duties
Number of subjects: 60
Study 20382280 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐supported treadmill training (BWSTT) for 4 weeks
Number of subjects: 18
Study 20382280 — intervention group
Group type: COMPARATOR
Intervention: General exercise program (control)
Number of subjects: 18
Study 18953465 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 45
Study 18953465 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of saccharides
Number of subjects: 45
Study 18953465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16148661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 47
Study 16148661 — intervention group
Group type: COMPARATOR
Intervention: Continuous flow 50% nitrous oxide (N(2)O)
Number of subjects: 47
Study 12511760 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 123
Study 12511760 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo intervention
Number of subjects: 123
Study 12511760 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 123
Study 11379469 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified short-course chemotherapy (S: streptomycin, H: isoniazid, R: Rifampicin, Z: pyrazinamide) for 2 months followed by 6 months of thiacetazone and isoniazid (2SHRZ/6TH or 2EHRZ/6TH)
Number of subjects: 97
Study 11379469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase of thiacetazone and isoniazid
Number of subjects: 97
Study 8862476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) breakfast
Number of subjects: 6
Study 8862476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat (HF) breakfast
Number of subjects: 6
Study 8862476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) breakfast
Number of subjects: 6
Study 1675867 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 19
Study 1675867 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 2.5, 5 or 10 mg twice daily
Number of subjects: 19
Study 1675867 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoteril 200 mg twice daily
Number of subjects: 19
Study 3885958 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 74
Study 3885958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 30160500 — intervention group
Group type: EXPERIMENTAL
Intervention: Low verbal descriptor
Number of subjects: 3390
Study 30160500 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Low verbal descriptor
Number of subjects: 3390
Study 30160500 — intervention group
Group type: EXPERIMENTAL
Intervention: No verbal descriptor
Number of subjects: 3390
Study 30160500 — intervention group
Group type: EXPERIMENTAL
Intervention: Various %ABV levels
Number of subjects: 3390
Study 30160500 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3390
Study 26979570 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion group (n=1824)
Number of subjects: 3754
Study 26979570 — intervention group
Group type: COMPARATOR
Intervention: Pre-/post-only group
Number of subjects: 3754
Study 26979570 — intervention group
Group type: COMPARATOR
Intervention: End-of-Project group
Number of subjects: 3754
Study 24750799 — intervention group
Group type: EXPERIMENTAL
Intervention: Guna‐Interleukin 4, Guna‐Interleukin 10, and Guna‐Interleukin 11 at the concentration of 10 fg/ml
Number of subjects: 48
Study 24750799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22442391 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) as a continuous variable
Number of subjects: 499
Study 22442391 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI≥30)
Number of subjects: 499
Study 22442391 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese group (BMI<30)
Number of subjects: 499
Study 21704105 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 with Infanrix hexa/Infanrix-IPV+Hib
Number of subjects: 0
Study 21704105 — intervention group
Group type: COMPARATOR
Intervention: PCV7 with Infanrix hexa/Infanrix-IPV+Hib
Number of subjects: 0
Study 21704105 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 and PCV7
Number of subjects: 0
Study 18358689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized hydromorphone
Number of subjects: 20
Study 18358689 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hydromorphone
Number of subjects: 20
Study 18358689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized saline
Number of subjects: 20
Study 17057556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain after a series of routine nursing interventions (clustered care)
Number of subjects: 43
Study 17057556 — intervention group
Group type: COMPARATOR
Intervention: Pain after a 30-minute rest period
Number of subjects: 43
Study 12917745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements for 12 months
Number of subjects: 99
Study 12917745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional supplements)
Number of subjects: 99
Study 10919170 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (30 g alcohol/day)
Number of subjects: 56
Study 10919170 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic solution (same degree of alcohol)
Number of subjects: 56
Study 10919170 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free red wine
Number of subjects: 56
Study 8737133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin (200 mg loading dose on day 1 followed by 100 mg daily)
Number of subjects: 686
Study 8737133 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg orally twice daily for 10 to 14 days)
Number of subjects: 686
Study 8737133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin
Number of subjects: 686
Study 8737133 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 686
Study 1570375 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptylinoxide (AT‐NO) IV
Number of subjects: 11
Study 1570375 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptylinoxide (AT‐NO) orally
Number of subjects: 11
Study 1570375 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg amitriptyline (AT) IV
Number of subjects: 11
Study 1570375 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with AT‐NO
Number of subjects: 11
Study 1570375 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with AT
Number of subjects: 11
Study 1570375 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal plasma clearance of AT‐NO
Number of subjects: 11
Study 6363735 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of designated auriculotherapy points
Number of subjects: 36
Study 30072277 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) postoperatively for five sessions of 30 minutes each.
Number of subjects: 52